The Most Advanced Drug Discovery Robot in the World
The world’s most advanced drug discovery robot is working alongside our scientists to help make drug discovery smarter, faster and cheaper. Designed to work three times more quickly than previous drug discovery robots, NiCoLA-B is also more scientist-friendly, flexible and responsive.
"We can configure NiCoLA-B to do our experiments in whatever way we want and we can interact with it while it’s working. It can sense our presence in a way that previous robots couldn’t, so it can share our workspace instead of being encased behind safety guarding." Paul Harper, Associate Principal Scientist – Screening Sciences at the Innovative Medicines and Early Development Biotech Unit.
A friendlier robot
Harper and his colleagues drew on decades of experience working with first generation robots to draw up their blueprint for NiCoLA-B. They wanted to swap the so-called ‘dumb robots’ originally designed for heavy lifting on production lines for a bespoke robotic system suited to the delicate manoeuvres and human interactions needed in drug discovery.
“We used to have to adjust our experiments to the way the robots worked, but NiCoLA-B has been designed to adapt to our way of working and collaborate with us. At any time, we can quickly inspect, interact and easily reconfigure it to our changing needs, so we’re in charge now!” Harper explains.
Through a mobile app, the team is able to ‘talk’ to NiCoLA-B and guide its decision-making – day or night, from their offices, homes, or even from the other side of the world.
NiCoLA-B – on duty 24/7
NiCoLA-B uses sound waves to move tiny droplets of potential drugs from storage tubes into miniature ‘wells’ on assay plates – billionths of a litre at a time. Next, droplets of cells or biochemical solutions are added to the wells. NiCoLA-B then oversees the interactions between the contents of the wells, checking for potential activity that could indicate a promising new drug.
Sharing NiCoLA-B with research partners
We are making NiCoLA-B available to our research partners through Open Innovation – our pioneering initiative for sharing our compounds, technology and expertise with academic and industry collaborators. The first research partners to work with NiCoLA-B are Cancer Research UK and the Medical Research Council. By combining our expertise, we are accelerating medicines research for the treatment of a range of diseases where there is a substantial unmet need.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018